ArticleDrugs in context2026
Corrigendum: SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.